ELCC 2022 – Lizza Hendriks

Lizza Hendriks discusses how clinical trials should be adapted considering the increasing use of brain metastasis screening in lung cancer patients, the immune micro-environment of CNS metastases, the role of the treatment sequence in the management of patients with brain lesions and summarizes how patients with low PD-L1 expression, frail/elderly patients and those with actionable mutations can be addressed, followed by depicting novel biomarkers for precision immunotherapy. 

Here is the full ELCC 2022 report.

More posts

Oncogene-driven lung cancer: EGFR, METex14, ROS1, RET

The neoadjuvant potential of the third-generation EGFR TKI osimertinib was assessed in the multicenter, single-arm, phase II NEOS study that included patients with resectable, stage II-IIIB N2, EGFR-mutant (ex19del/L858R) adenocarcinoma of the lung. Forty patients received osimertinib 80 mg QD for 6 weeks prior to surgery.

Looking more closely at upcoming and established immunotherapy standards

Adjuvant treatment using immune checkpoint inhibition after complete resection of early-stage lung cancer is being investigated considering the modest survival benefit conferred by platinum-based combination chemotherapy in this setting. IMpower010 was the first phase III immunotherapy study to demonstrate a significant disease-free survival (DFS) improvement in the adjuvant setting after platinum-based chemotherapy. Patients included in this trial had undergone complete resection of stage IB-IIIA NSCLC and subsequently received 1–4 cycles of cis­platin-based chemotherapy.

Preface

The European Lung Cancer Congress (ELCC) that took place virtually on 30th March – 2nd April 2022 effectively disseminated the latest advances in lung and thoracic malignancies and gave 131 speakers from all around the world the chance to present promising new research avenues as well as the opportunity for discussions and new perspectives.